1. Kim KS, Park SW, Cho YW, Kim SK. Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus. Diabetes Metab J 2018;42:224-232.
Article PubMed PMC
2. Bae JC. Trends of diabetes epidemic in Korea. Diabetes Metab J 2018;42:377-379.
Article PubMed PMC
3. Kim KJ, Kwon TY, Yu S, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS, Kim SG, Park Y, Kim NH. Ten-year mortality trends for adults with and without diabetes mellitus in South Korea, 2003 to 2013. Diabetes Metab J 2018;42:394-401.
Article PubMed PMC
4. Kim BY, Won JC, Lee JH, Kim HS, Park JH, Ha KH, Won KC, Kim DJ, Park KS. Diabetes fact sheets in Korea, 2018: an appraisal of current status. Diabetes Metab J 2019;43:487-494.
Article PubMed PMC
5. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-735.
Article PubMed
6. Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013. Diabetes Obes Metab 2016;18:607-614.
Article PubMed
7. Hung SC, Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol 2015;3:605-614.
Article PubMed
8. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl 1):S90-S102.
Article PubMed
9. U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function cited 2020 Jan 28. Available from:
http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm.
10. Packer M. Is metformin beneficial for heart failure in patients with type 2 diabetes? Diabetes Res Clin Pract 2018;136:168-170.
Article PubMed
11. Aharaz A, Pottegard A, Henriksen DP, Hallas J, Beck-Nielsen H, Lassen AT. Risk of lactic acidosis in type 2 diabetes patients using metformin: a case control study. PLoS One 2018;13:e0196122.
Article PubMed PMC
12. Lee EY, Hwang S, Lee YH, Lee SH, Lee YM, Kang HP, Han E, Lee W, Lee BW, Kang ES, Cha BS, Lee HC. Association between metformin use and risk of lactic acidosis or elevated lactate concentration in type 2 diabetes. Yonsei Med J 2017;58:312-318.
Article PubMed PMC
13. Tseng CH. Metformin use is associated with a lower risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Am Heart Assoc 2019;8:e011640.
Article PubMed PMC
14. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999;16:273-281.
Article PubMed
15. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983;34:827-834.
Article PubMed
16. Richy FF, Sabido-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care 2014;37:2291-2295.
Article PubMed
17. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87.
Article PubMed
18. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010;33:727-740.
Article PubMed
19. Lalau JD, Kajbaf F, Protti A, Christensen MM, De Broe ME, Wiernsperger N. Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes Obes Metab 2017;19:1502-1512.
Article PubMed
21. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 2018;41:547-553.
Article PubMed
22. Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, Park SO, Hur KY, Chon S, Moon MK, Kim NH, Kim SY, Rhee SY, Lee KW, Kim JH, Rhee EJ, Chun S, Yu SH, Kim DJ, Kwon HS, Park KS. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J 2019;43:398-406.
Article PubMed PMC
23. Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME. Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. Radiology 2008;248:106-113.
Article PubMed
24. Davenport MS, Khalatbari S, Cohan RH, Ellis JH. Contrast medium-induced nephrotoxicity risk assessment in adult inpatients: a comparison of serum creatinine level- and estimated glomerular filtration rate-based screening methods. Radiology 2013;269:92-100.
Article PubMed PMC
25. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol 1998;4:65-69.
PubMed
26. Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology 2000;216:481-484.
Article PubMed
27. Baumgarten DA, Ellis JH. Contrast-induced nephropathy: contrast material not required. AJR Am J Roentgenol 2008;191:383-386.
Article PubMed
28. Davenport MS, Cohan RH, Khalatbari S, Ellis JH. The challenges in assessing contrast-induced nephropathy: where are we now? AJR Am J Roentgenol 2014;202:784-789.
Article PubMed
29. Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. AJR Am J Roentgenol 2009;192:1544-1549.
Article PubMed
30. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 2010;256:21-28.
Article PubMed
31. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 2014;271:65-73.
Article PubMed
32. Newhouse JH, RoyChoudhury A. Quantitating contrast medium-induced nephropathy: controlling the controls. Radiology 2013;267:4-8.
Article PubMed
33. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235:843-849.
Article PubMed
34. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009;251:697-704.
Article PubMed PMC
35. Haight AE, Kaste SC, Goloubeva OG, Xiong XP, Bowman LC. Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation. Radiology 2003;226:399-404.
Article PubMed
36. Senthilnathan S, Gauvreau K, Marshall AC, Lock JE, Bergersen L. Contrast administration in pediatric cardiac catheterization: dose and adverse events. Catheter Cardiovasc Interv 2009;73:814-820.
Article PubMed PMC
38. Shah AD, McHargue C, Yee J, Rushakoff RJ. Intravenous contrast in patients with diabetes on metformin: new common sense guidelines. Endocr Pract 2016;22:502-505.
Article PubMed
39. Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010;254:261-269.
Article PubMed
42. Han S, Yoon SH, Lee W, Choi YH, Kang DY, Kang HR. Management of adverse reactions to iodinated contrast media for computed tomography in Korean referral hospitals: a survey investigation. Korean J Radiol 2019;20:148-157.
Article PubMed
43. Corremans R, Vervaet BA, D'Haese PC, Neven E, Verhulst A. Metformin: a candidate drug for renal diseases. Int J Mol Sci 2018;20:E42
Article
44. Korea Ministry of Food and Drug Safety: Instructions on the change of permit for metformin hydrochloride (tablet) (uniform adjustment) updated 2018 Jan 3. Available from:
https://nedrug.mfds.go.kr/bbs/58/2683/.